Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

Next Previous
Trial Profile

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tanezumab (Primary) ; Tanezumab (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; Registrational; Therapeutic Use

Most Recent Events

  • 09 Oct 2021 Results of a subgroup analysis of pooled data from phase III placebo-controlled trials (NCT02697773, NCT02709486, and NCT01089725 (only safety) assessing the impact of pre-specified patient characteristics on efficacy and safety of subcutaneous tanezumab in patients with osteoarthritis published in the International Journal of Clinical Practice
  • 22 Apr 2021 Results of a pooled analysis (NCT01089725, NCT02697773, NCT02709486 and NCT02528188) assessing the peripheral nerve safety of subcutaneous tanezumab versus placebo or nonsteroidal anti-inflammatory drugs presented at the 73rd Annual Meeting of the American Academy of Neurology
  • 03 Nov 2020 Results of a pooled analysis of data pooled from 6 trials assessing the relative efficacy and tolerability of 2.5, 5, and 10 mg tanezumab for the treatment of osteoarthritis published in the International Journal of Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top